Phase II Clinical Trial of OCH-NCNP1
Efficacy and Safety of OCH-NCNP1 in Patients With Relapsing Multiple Sclerosis
Sponsor: National Center of Neurology and Psychiatry, Japan
A PHASE2 clinical study on Multiple Sclerosis, Relapsing-Remitting and Multiple Sclerosis, Secondary Progressive, this trial is completed. The trial is conducted by National Center of Neurology and Psychiatry, Japan and has accumulated 9 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2022 — Dec 2023 [monthly]
Active Not Recruiting PHASE2
Status: Enrolling By Invitation → Active Not Recruiting
-
May 2022 — Oct 2022 [monthly]
Enrolling By Invitation PHASE2
▶ Show 4 earlier versions
-
Apr 2021 — May 2022 [monthly]
Enrolling By Invitation PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Enrolling By Invitation PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Enrolling By Invitation PHASE2
-
Jan 2020 — Sep 2020 [monthly]
Enrolling By Invitation PHASE2
First recorded
Dec 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Center of Neurology and Psychiatry, Japan
For direct contact, visit the study record on ClinicalTrials.gov .